"573768" . . "surgical castration; malignant ovarial carcinomas; ovarial carcinoma; estrogens deficit; hormonal replacement therapy; HRT; HRT indication"@en . "M\u00EDsto hormon\u00E1ln\u00ED substitu\u010Dn\u00ED l\u00E9\u010Dby u pacientek l\u00E9\u010Den\u00FDch pro zhoubn\u00FD n\u00E1dor ovaria" . "8" . . "4"^^ . "RIV/00843989:_____/04:00012021" . "1211-6645" . "Koliba, Peter" . . . . "\u0160ev\u010D\u00EDk, Libor" . "[561740C6C866]" . . "4" . "V" . . "4"^^ . "M\u00EDsto hormon\u00E1ln\u00ED substitu\u010Dn\u00ED l\u00E9\u010Dby u pacientek l\u00E9\u010Den\u00FDch pro zhoubn\u00FD n\u00E1dor ovaria" . . "RIV/00843989:_____/04:00012021!RIV09-MZ0-00843989" . "CZ - \u010Cesk\u00E1 republika" . "M\u00EDsto hormon\u00E1ln\u00ED substitu\u010Dn\u00ED l\u00E9\u010Dby u pacientek l\u00E9\u010Den\u00FDch pro zhoubn\u00FD n\u00E1dor ovaria"@cs . . "3"^^ . "M\u00EDsto hormon\u00E1ln\u00ED substitu\u010Dn\u00ED l\u00E9\u010Dby u pacientek l\u00E9\u010Den\u00FDch pro zhoubn\u00FD n\u00E1dor ovaria"@cs . . "Auto\u0159i pojedn\u00E1vaj\u00ED o vlastn\u00EDch zku\u0161enostech s pod\u00E1v\u00E1n\u00EDm substitu\u010Dn\u00ED terapie pacientk\u00E1m do 55 let v\u011Bku po iatrogenn\u011B navozen\u00E9 menopauze p\u0159i l\u00E9\u010Db\u011B onkologick\u00FDch malignit (chirurgick\u00E9 odstran\u011Bn\u00ED ovari\u00ED, nebo jejich po\u0161kozen\u00ED radioterapi\u00ED nebo chemoterapi\u00ED). Deficit estrogenu zvy\u0161uje riziko osteopor\u00F3zy, ateroskler\u00F3zy a kardiovaskul\u00E1rn\u00EDch chorob a sni\u017Euje kvalitu \u017Eivota menopauz\u00E1ln\u00EDmi projevy. Ve shod\u011B s poznatky z odborn\u00E9 literatury doporu\u010Duj\u00ED pod\u00E1v\u00E1n\u00ED HRT s co nejni\u017E\u0161\u00ED \u00FA\u010Dinnou d\u00E1vkou estrogen\u016F pacientk\u00E1m l\u00E9\u010Den\u00FDm pro karcinom ovari\u00ED, pouze v p\u0159\u00EDpad\u011B endometroidn\u00EDch karcinom\u016F pod\u00E1v\u00E1n\u00ED nedoporu\u010Duj\u00ED" . . "Dan\u010D\u00EDkov\u00E1, Zdenka" . . "Praktick\u00E1 gynekologie" . . . "Auto\u0159i pojedn\u00E1vaj\u00ED o vlastn\u00EDch zku\u0161enostech s pod\u00E1v\u00E1n\u00EDm substitu\u010Dn\u00ED terapie pacientk\u00E1m do 55 let v\u011Bku po iatrogenn\u011B navozen\u00E9 menopauze p\u0159i l\u00E9\u010Db\u011B onkologick\u00FDch malignit (chirurgick\u00E9 odstran\u011Bn\u00ED ovari\u00ED, nebo jejich po\u0161kozen\u00ED radioterapi\u00ED nebo chemoterapi\u00ED). Deficit estrogenu zvy\u0161uje riziko osteopor\u00F3zy, ateroskler\u00F3zy a kardiovaskul\u00E1rn\u00EDch chorob a sni\u017Euje kvalitu \u017Eivota menopauz\u00E1ln\u00EDmi projevy. Ve shod\u011B s poznatky z odborn\u00E9 literatury doporu\u010Duj\u00ED pod\u00E1v\u00E1n\u00ED HRT s co nejni\u017E\u0161\u00ED \u00FA\u010Dinnou d\u00E1vkou estrogen\u016F pacientk\u00E1m l\u00E9\u010Den\u00FDm pro karcinom ovari\u00ED, pouze v p\u0159\u00EDpad\u011B endometroidn\u00EDch karcinom\u016F pod\u00E1v\u00E1n\u00ED nedoporu\u010Duj\u00ED"@cs . "The authors discuss their own experience with the administration of hormonal replacement therapy to the patients to the age of 55 after iatrogenously induced menopause during the treatment of oncological malignities (surgical removal of the ovaries or the insult of radiotherapy or chemotherapy). Estrogen deficit increases the risk of osteoporosis, atherosclerosis and cardiovascular diseases and decreases the quality of life by the menopausal symptoms. In accordance with the findings from the professional literature they reccomend HRT administration to the patients treated with ovarial carcinoma while the dose estrogen must be as low as possible, only in case of endometroid carcinomas they do not reccomend its administration."@en . . . "The role of hormonal replacement therapy in patients with ovarial carcinoma"@en . "Kl\u00E1t, Jaroslav" . "The role of hormonal replacement therapy in patients with ovarial carcinoma"@en . . . . . .